China-based CAR-T Cell therapy achieves breakthrough clinical trial results

Share This Post

June 2016: Professor Huang He of Zhejiang University’s First Affiliated Hospital presented the outcomes of 10 clinical cases, including CAR-T cell therapy for leukaemia treatment, at the 2016 Haematogenic Immunity Summit in Hangzhou from April 22 to 24, 2016. This is the first time that the entire clinical trial data set has been made publicly available.

In June 2015, the hospital and Innovative Cellular Therapeutics (ICT) received clinical ethics approval for the trial, which then enrolled its first patient. The tenth patient had achieved complete remission by April 2016.

The study team completed CAR-T cell reinfusion and conducted preliminary evaluations on ten patients with relapsed or refractory B lymphoblastic leukaemia during the 10-month clinical trials.
A third-party clinical research organization independently oversaw the clinical trial, which was done in strict conformity with clinical ethical guidelines. ICT covered all patient costs associated with the CAR-T experiment. Nine of the ten patients obtained complete remission, and the minimal residual disease (MRD) in eight of them became negative, indicating that the treatment was effective. Both the complete remission rate of 90% and the MRD-negative rate of 80% were higher than the greatest outcomes ever recorded globally.

All ten patients, who ranged in age from 17 to 57, had relapsed or refractory B lymphocytic leukaemia and were given only a few months to live. The tenth and final patient is a 17-year-old woman who began participating in the CAR-T clinical trial in March of this year. Following the collection of her blood, researchers genetically modified her common T-cells to express a protein known as Chimeric Antigen Receptor (CAR). CAR can direct specific T-cells to locate, identify, and kill malignant tumour cells in the same way as GPS can. Common T-cells were turned into “cancer-fighting” CAR-T cells thanks to the use of this technology.
The modified CAR-T cells were administered into the patient’s body in early April 2016, and the ‘cytokine storm’ occurred as predicted by the study team. The patient developed symptoms such as fever, muscle soreness, and hypoxemia as the CAR-T cells rapidly expanded in his body and generated a huge amount of cytokines. These signs suggested that the use of CAR-T cells was having a beneficial effect. She was found to be MRD-negative after the further tests revealed that she was in complete remission.
Innovative Cellular Therapeutics, in partnership with Zhejiang University’s First Affiliated Hospital, has made significant progress in the development of CAR-T therapy. ICT is conducting clinical studies at seven different institutions around China for relapsed and refractory acute lymphocytic leukaemia, and has finished the trial and collected preliminary data on 23 patients with severe disease. Twenty individuals, or 87 percent of the overall study population, experienced complete leukaemia remission.
Only three companies in the world (Novartis, Juno, and Kite Pharma), all based in the United States, had developed similar levels of CAR-T treatment for leukaemia prior to the trial. ICT, a Chinese company, has now joined that illustrious company as one of the global leaders in CAR-T treatment applications.
ICT will now focus on a new clinical trial for the treatment of lymphoma, based on the results of its leukaemia trial. In the future, ICT will concentrate its research and development efforts on solid tumours such as colorectal cancer, breast cancer, gastric cancer, and esophageal cancer.
CAR-T cellular therapy is quickly gaining traction among doctors, researchers, patients, and the general public as the world’s most promising tumour precision medicine, and it is predicted to benefit more patients with cancer in the future.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer
Bladder cancer

Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer

“Nogapendekin Alfa Inbakicept-PMLN, a novel immunotherapy, shows promise in treating bladder cancer when combined with BCG therapy. This innovative approach targets specific cancer markers while leveraging the immune system’s response, enhancing the efficacy of traditional treatments like BCG. Clinical trials reveal encouraging results, indicating improved patient outcomes and potential advancements in bladder cancer management. The synergy between Nogapendekin Alfa Inbakicept-PMLN and BCG heralds a new era in bladder cancer treatment.”

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy